Open AccessBasal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts
Author(s) -
Federica Guffanti,
M.F. Alvisi,
Alessia Anastasia,
Francesca Ricci,
Michela Chiappa,
Alba LlopGuevara,
Violeta Serra,
Robert Fruscio,
Andrea Degasperi,
Sereik-Zainal,
Maria Rosa Bani,
Michela Lupia,
Raffaella Giavazzi,
Eliana Rulli,
Giovanna Damia
Publication year - 2021
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/s41416-021-01609-1
Subject(s) - olaparib , rad51 , ovarian cancer , cancer research , biomarker , medicine , parp inhibitor , cisplatin , oncology , cancer , biology , dna damage , pathology , poly adp ribose polymerase , chemotherapy , gene , polymerase , dna , genetics
The search for biomarkers to evaluate ovarian cancer (OC) homologous recombination (HR) function and predict the response to therapy is an urgent clinical need to improve the selection of patients who could benefit from platinum- and olaparib (poly-ADP ribose polymerase inhibitors, PARPi)-based therapies.